GlassScriptPhysician profile
Kathryn E Baumgartner
NPI 1194349969
$3,075.42
in general payments reported to CMS, 2019-2025
26 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.61 · 2021: $22.47 · 2022: $402 · 2023: $128 · 2024: $1,122 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.64 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $449.13 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $282.88 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $215.03 | 2022-2025 | |
| Lilly USA, LLC | $207.96 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $194.80 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.68 | 2024-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $107.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $100.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $91.68 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $90.96 | 2021-2024 | Gardasil 9, Gardasil, Proquad |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.85 | 2024-2025 | Caplyta |
| Abbott Laboratories | $82.71 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $76.41 | 2025 | Auvelity |
| Eisai INC. | $64.30 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $52.54 | 2023 | Myrisk |
| Glaxosmithkline, LLC. | $44.19 | 2024-2025 | Shingrix, Bexsero, Arexvy |
| Novartis Pharmaceuticals Corporation | $33.82 | 2025 | |
| Averitas Pharma INC. | $23.88 | 2024 | Qutenza |
| Dexcom, INC. | $22.53 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $20.61 | 2020 | |
| Biogen, INC. | $18.43 | 2024 | Skyclarys |
| Kyowa Kirin, INC. | $16.93 | 2025 | |
| Phadia US INC. | $15.43 | 2025 | Immunocap |
| Coloplast Corp | $14.31 | 2024 | |
| Phathom Pharmaceuticals, INC. | $13.80 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Baumgartner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.